These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9378161)

  • 1. Evaluation of phosphohexose isomerase as a metastasis marker in breast cancer patients.
    Yasasever V; Dinçer M; Camlica H; Duranyildiz D; Dalay N
    Eur J Gynaecol Oncol; 1997; 18(5):397-9. PubMed ID: 9378161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A profile of serum CA 15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer.
    Buamah PK; Bent DJ; Bodger WA; Skillen AW
    J Surg Oncol; 1993 Jun; 53(2):84-7. PubMed ID: 8099132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma.
    Rodríguez de Paterna L; Arnaiz F; Estenoz J; Ortuño B; Lanzós E
    Int J Biol Markers; 1995; 10(1):24-9. PubMed ID: 7629423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The determination of phosphohexose isomerase in patients with cancer of breast and uterus. A comparison with other tests (author's transl)].
    Telesforo P; Rosenberg R
    Quad Sclavo Diagn; 1978 Sep; 15(3):365-72. PubMed ID: 37546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen and phosphohexose isomerase, gammaglutamyl transpeptidase and lactate dehydorgenase levels in patients with and without liver metastases.
    Munjal D; Chawla PL; Lokich JJ; Zamcheck N
    Cancer; 1976 Apr; 37(4):1800-7. PubMed ID: 4219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
    Paulick R; Caffier H; Paulick M
    Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
    Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of serum phosphohexose isomerase in gastrointestinal cancer at different stages.
    Baumann M; Brand K; Giedl J; Hermanek P; Ruf S; Scheele J; Hoferichter S; Gall FP
    Oncology; 1988; 45(3):153-8. PubMed ID: 3368192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphohexose isomerase and carcinoembryonic antigen in the sera of patients with primary lung cancer.
    Santabárbara P; Molina R; Estapé J; Ballesta AM
    Int J Biol Markers; 1988; 3(2):113-22. PubMed ID: 3243977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
    Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
    Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of cancer markers in the detection and prognosis of digestive system tumors].
    de Mello Júnior JP; Giles GR
    Arq Gastroenterol; 1986; 23(3):133-44. PubMed ID: 2449153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.